MX2018010288A - Transposon system and methods of use. - Google Patents

Transposon system and methods of use.

Info

Publication number
MX2018010288A
MX2018010288A MX2018010288A MX2018010288A MX2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A MX 2018010288 A MX2018010288 A MX 2018010288A
Authority
MX
Mexico
Prior art keywords
methods
immune cell
transposon system
sequence encoding
dna sequence
Prior art date
Application number
MX2018010288A
Other languages
Spanish (es)
Inventor
Shedlock Devon
Hermanson David
Ostertag Eric
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of MX2018010288A publication Critical patent/MX2018010288A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
MX2018010288A 2016-02-26 2017-02-24 Transposon system and methods of use. MX2018010288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300387P 2016-02-26 2016-02-26
PCT/US2017/019531 WO2017147538A1 (en) 2016-02-26 2017-02-24 Transposon system and methods of use

Publications (1)

Publication Number Publication Date
MX2018010288A true MX2018010288A (en) 2019-06-06

Family

ID=58314517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010288A MX2018010288A (en) 2016-02-26 2017-02-24 Transposon system and methods of use.

Country Status (12)

Country Link
EP (1) EP3420090A1 (en)
JP (1) JP2019506177A (en)
KR (1) KR20180131545A (en)
CN (1) CN109312361A (en)
AU (1) AU2017224111A1 (en)
BR (1) BR112018067536A2 (en)
CA (1) CA3015642A1 (en)
IL (1) IL261343A (en)
MX (1) MX2018010288A (en)
RU (1) RU2018133691A (en)
SG (1) SG11201807134RA (en)
WO (1) WO2017147538A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
CN108728477B (en) * 2017-04-24 2022-02-22 华东理工大学 Efficient transposition mutation system and construction method
US20210115453A1 (en) * 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
JP2020532987A (en) * 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド Compositions and Methods for Chimeric Ligand Receptor (CLR) -mediated Conditional Gene Expression
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
JP2021527427A (en) 2018-06-21 2021-10-14 ビー−モーゲン・バイオテクノロジーズ，インコーポレーテッド Transposon-mediated gene transfer and related compositions, systems, and methods of the enhanced hAT family
CN111926041B (en) * 2020-10-16 2020-12-25 广州吉妮欧生物科技有限公司 SARS-CoV-2 pseudovirus mouse internal packaging system and its preparation method
CN114246986B (en) * 2021-12-29 2022-08-23 中国人民解放军陆军军医大学 Cardiovascular implant based on in-situ immune response regulation and control and preparation method thereof
CN116590341A (en) * 2023-07-13 2023-08-15 山东维真生物科技有限公司 adenovirus-PiggyBac system and preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP5726522B2 (en) 2007-07-04 2015-06-03 マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン Transposon system-a hyperactive variant of the sleeping beauty transposase protein
US20110311506A1 (en) * 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
EP3184632B1 (en) * 2009-02-26 2024-04-03 Poseida Therapeutics, Inc. Hyperactive piggybac transposases
US20130045491A1 (en) * 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression

Also Published As

Publication number Publication date
BR112018067536A2 (en) 2019-02-05
RU2018133691A3 (en) 2020-07-29
AU2017224111A1 (en) 2018-09-13
EP3420090A1 (en) 2019-01-02
IL261343A (en) 2018-10-31
KR20180131545A (en) 2018-12-10
CA3015642A1 (en) 2017-08-31
SG11201807134RA (en) 2018-09-27
RU2018133691A (en) 2020-03-26
WO2017147538A1 (en) 2017-08-31
JP2019506177A (en) 2019-03-07
CN109312361A (en) 2019-02-05

Similar Documents

Publication Publication Date Title
MX2018010288A (en) Transposon system and methods of use.
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2017014125A (en) Alpha-amylase variants and polynucleotides encoding same.
WO2015191693A3 (en) Method for gene editing
MX2023001119A (en) Enzyme variants and polynucleotides encoding the same.
MY197846A (en) Optimized mini-dystrophin genes and expression cassettes and their use
WO2015157579A3 (en) Enhanced nucleic acid constructs for eukaryotic gene expression
MX2018004263A (en) Multiplexed genome editing.
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2015155686A3 (en) Methods and compositions for rna-directed repression of transcription using crispr-associated genes
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2017003847A (en) Protease-activatable bispecific proteins.
MX2022003908A (en) Enzymes and applications thereof.
MX2015017110A (en) Targeted integration.
WO2017062668A3 (en) Dna vectors, transposons and transposases for eukaryotic genome modification
NZ742068A (en) Transposon system, kit comprising the same, and uses thereof
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
MX2017007105A (en) Lipase variants and polynucleotides encoding same.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
WO2016130628A8 (en) Griffithsin mutants
PH12018500155A1 (en) Recombinant orf virus vector
PH12017500047A1 (en) Dual cistronic bacterial expression system